Business Wire

French Ministry of the Interior Selects IDEMIA and Sopra Steria to Develop a New Standard Border Control System

Share

CCAF is an ambitious project seeking to install a high-performance standard system so that all border control activities can be properly coordinated and harmonized. It will be rolled out in France during 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005909/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

While assuring border controls’ underlying need for security and accuracy, CCAF’s development will also focus on interoperability and scalability. It will be so designed that it can cope with future French and EU regulatory changes and growth in traveller traffic in and out of mainland and overseas France.

Underpinned by biometric recognition, the system will minimize traveller time spent passing through border controls without having to hire further guards on French borders.

IDEMIA and Sopra Steria will join forces tapping into their ID management expertise, especially in relation to border security, and their French critical systems in-depth know-how.

There is a lot at stake with the CCAF project including a need to factor in high flexibility and responsiveness when developing EU IT systems in view of upcoming world sports events like the 2023 Rugby World Cup and the 2024 Paris Olympics. With this joint project, the Ministry placed their trust in the consortium’s skill and expertise in meeting highly demanding business, tech and regulatory needs and tight milestone deadlines.

“We are very grateful to the French Ministry of the Interior for having trusted our know-how and expertise in automated border-crossing controls. The CCAF project aims to develop and perfect a standard and robust border system that is both smoother and more secure. Together with our partner Sopra Steria, we pledge to provide a groundbreaking system that delivers a high level of security and an enhanced travel experience.” said Pascal Fallet, IDEMIA Senior VP Europe, Public Security and Identity.

“Having served the Ministry of the Interior over many years, we are immensely proud to be selected with our partner IDEMIA to develop and roll out the new standard border control system. IDEMIA’s skills and know-how as biometrics world leader fit very well with our own skills as reputed big government systems integrator in complex environments. This will be a great asset to ensure the project’s success. Together with IDEMIA we pledge to develop a reliable and secure system that sustainably delivers on required service quality by harnessing all necessary state-of-the-art technologies.” said Georges Wakim, Sopra Steria Security Market Director.

In France, IDEMIA is currently responsible for the passenger automated border control tracking system and the visa and asylum application data processing system. IDEMIA also regularly conducts pilot tests with various private and public sector parties including Aéroports de Paris (ADP Group), Air France and recently Lyon Aéroports (MONA by Vinci Airports) with a view to biometrics improving the airport’s passenger experience.

Meanwhile, Sopra Steria frequently serves the French Ministry of the Interior bringing many famous projects to fruition. For instance, the Group helps develop the Schengen border system working with various other EU Member States, develops and delivers security file search apps for French police forces and works to enhance French road safety and management of foreign migrants.

Last June, IDEMIA and Sopra Steria were picked by EU agency eu-LISA to develop the new shared Biometric Matching System (sBMS), on which Schengen Area border security is based.

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter

About Sopra Steria

Sopra Steria, a European leader in consulting, digital services and software development, helps its clients drive their digital transformation and obtain tangible and sustainable benefits. It provides end-to-end solutions to make large companies and organisations more competitive by combining in-depth knowledge of a wide range of business sectors and innovative technologies with a fully collaborative approach. Sopra Steria places people at the heart of everything it does and is committed to putting digital to work for its clients in order to build a positive future for all. With 46,000 employees in 25 countries, the Group generated revenue of €4.4 billion in 2019.

The world is how we shape it.

Sopra Steria (SOP) is listed on Euronext Paris (Compartment A) – ISIN: FR0000050809

To learn more, go to https://www.soprasteria.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contacts
IDEMIA:
Hanna SEBBAH
idemia@havas.com
+33 (0) 6 63 73 30 30

Sopra Steria :
Elsa ESTAGER
elsa.estager@soprasteria.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye